Healthcare
Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development
Kevin Norrett, a proven leader in advancing corporate strategy through value-creating transactions, will be appointed as Chief Business OfficerCharles Carter promoted to Chief Financial Officer, reflecting his strong leadership and oversight of Ovid’s financial operations, following Jeffrey Rona’s transition to an advisory roleEliseo Salinas, MD, joined as Executive R&D Advisor, building on a distinguished career leading the development of multiple, breakthrough neurologic and psychiatric medici
About this update from Ovid Therapeutics Inc.
NEW YORK, July 08, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today announced several strategic appointments strengthening its executive leadership team to support the Company's next phase of development. Kevin Norrett, MS, MBA, will join Ovid as Chief Business Officer to spearhead business and corporate development functions as well as strategic partnerships. Charles Carter, MS, MBA, was promoted to Chief Financial Officer, and will lead business and financial operations. Charles succeeds Jeffrey Rona, who will remain a long-term advisor to the Company through 2027 to ensure a smooth operational transition. Building on his prior role as an advisor to the Company, Eliseo Salinas, MD, MSc, has joined as Executive R&D Advisor, providing strategic and operational guidance for the Company's research and development programs. Victoria Fort was promoted to Chief Strategy Officer, leading enterprise strategy, investor relations, and operational growth initiatives. "With the progress across our clinical development programs, we are adding to a world-class team of experienced leaders who are dedicated to driving Ovid's success," said Meg Alexander, President and Chief Executive Officer of Ovid Therapeutics. "I am thrilled to welcome Kevin and Eliseo to Ovid, two industry veterans with impressive track records of delivering novel therapeutics to patients. Kevin's expertise in realizing high-impact collaborations and transactions will strengthen our efforts to accelerate the characterization and value creation of our programs, while Eliseo's experience successfully developing medicines for intractable psychiatric and neurological conditions is invaluable as we advance our KCC2 activators, she added. "I'd also like to congratulate Charles and Victoria on their expanded leadership roles. Their deep understanding of Ovid's business further positions us to execute on our strategy. I am grateful to Jeff for his partnership and many contributions to Ovid, including his commitment to serve as an ongoing advisor. His creativity in structuring strategic transactions and thoughtful guidance helped build the strong foundation we have today. Together, this team brings the experience, execution, and focus needed to deliver our potential medicines to patients."
View stock analysis, news, and events for Ovid Therapeutics Inc.